Genmab and BioNTech announced the initial data from the phase II GCT1046-04 trial, which evaluated the efficacy of acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311.
Acasunlimab is an investigational bispecific antibody, which aims to elicit an antitumor response through conditional activation of 4-1BB on T cells and natural killer (NK) cells, which is stringently based on simultaneous binding of the PD-L1 arm.
Go deeper with GlobalData
The GCT1046-04 clinical trial is an open-label study evaluating the safety and efficacy of acasunlimab in patients with relapsed/refractory mNSCLC.
The randomised trial assessed the acasunlimab both as a monotherapy and in combination with pembrolizumab, in patients with PD-L1-positive metastatic non-small cell lung cancer (mNSCLC) who had progressed after one or more previous anti-PD(L)1 containing treatments.
The trial showed an overall survival rate of 69% over 12 months, a median overall survival of 17.5 months, and an overall response rate of 30% in patients treated with the combination therapy every six weeks.
It involved 113 patients across three arms, with the objective response analysis conducted for 62 centrally confirmed PD-L1-positive efficacy-evaluable patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn the Phase II study, Arm A, which involved acasunlimab monotherapy, showed a median overall survival of 5.5 months, a 50% disease control rate, and a 31% overall response rate.
Arm B, which combined acasunlimab with pembrolizumab every three weeks, resulted in an 8.6-month median overall survival, a 59% disease control rate, and a 21% overall response rate.
With the combination administered every six weeks, Arm C demonstrated the most significant outcomes, including the 17.5-month median overall survival, a 75% disease control rate, and a 30% overall response rate.
The anti-tumor activity was observed across various patient subgroups and the adverse events reported were consistent with the known safety profiles of the individual drugs.
Genmab executive vice-president and chief development officer Judith Klimovsky said: “The initial results of acasunlimab in combination with pembrolizumab administered every six weeks suggest a potential meaningful impact on patients with metastatic non-small cell lung cancer.
“We will continue to evaluate these data to inform further development of acasunlimab including a planned Phase III trial as we remain committed to investigating acasunlimab as a potential treatment option.”
Last year, Genmab and Seagen reported additional positive results from the Phase III clinical trial of Tivdak for the treatment of recurrent or metastatic cervical cancer.
